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Department of Infectious Diseases, Portland, 7) Decision Research, Eugene, OR and 8) University of Washington, Seattle, WA, USAAbstractIncreasing morbidity related to Clostridium difﬁcile infection (CDI) has heightened interest in the identiﬁcation of patients who would most
beneﬁt from recognition of risk and intervention. We sought to develop and validate a prognostic risk score to predict CDI risk for
individual patients following an outpatient healthcare visit. We assembled a cohort of Kaiser Permanente Northwest (KPNW) patients
with an index outpatient visit between 2005 and 2008, and identiﬁed CDI in the year following that visit. Applying Cox regression, we
synthesized a priori predictors into a CDI risk score, which we validated among a Kaiser Permanente Colorado (KPCO) cohort. We
calculated and plotted the observed 1-year CDI risk for each decile of predicted risk for both cohorts. Among 356 920 KPNW patients,
608 experienced CDI, giving a 1-year incidence of 2.2 CDIs per 1000 patients. The Cox model differentiated between patients who do
and do not develop CDI: there was a C-statistic of 0.83 for KPNW. The simpler points-based risk score, derived from the Cox model,
was validated successfully among 296 550 KPCO patients, with no decline in the area under the receiver operating characteristic curve:
0.785 (KPNW) vs. 0.790 (KPCO). The predicted risk for CDI agreed closely with the observed risk. Our CDI risk score utilized data
collected during usual care to successfully identify patients who developed CDI, discriminating them from patients at the lowest risk for
CDI. Our prognostic CDI risk score provides a decision-making tool for clinicians in the outpatient setting.
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E-mail: jennifer.l.kuntz@kpchr.orgIntroductionClostridium difﬁcile infection (CDI) is recognized as a signiﬁcant
cause of morbidity and mortality [1]. Antimicrobial use,Microbiol Infect 2015; 21: 256–262
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.001advanced age, underlying and severe comorbidity and pro-
longed hospitalization are well-known predictors of CDI [2–7];
however, physicians lack a tool that can quantify a patient’s risk
on the basis of demographic characteristics and medical history.
Although risk scores have commonly been developed to
identify populations at high risk for chronic disease or its
complications [8–11], prognostic risk modelling has been used
less frequently for infectious diseases. Several scores have been
created to identify hospitalized patients at risk for incident and
recurrent CDI [12–17], but no risk prediction score has beenious Diseases. Published by Elsevier Ltd. All rights reserved
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patients.
Risk prediction in the ambulatory setting could allow clini-
cians to identify patients at the highest risk for CDI and modify
individual risk factors, such as antimicrobial use, before these
patients become ill. Patients at high risk for CDI could also be
targeted for education about their CDI risk and recognition of
symptoms. Our objective was to develop and validate a prog-
nostic risk score that can be used to quantify the 1-year risk of
CDI by using patient characteristics that are readily available
during routine care delivery.Study population and methodsStudy design and patient selection
We conducted a cohort study among Kaiser Permanente
Northwest (KPNW) members to develop a CDI risk score
based on factors present during an outpatient visit that impact
on the development of CDI. We then validated the risk score
among a similarly deﬁned cohort of Kaiser Permanente Colo-
rado (KPCO) patients.
We selected patients with one or more outpatient primary
or specialty care visits between 1 June 2005 and 30 September
2008, a time period during which both KPNW and KPCO used
the same C. difﬁcile testing approaches. For patients having
multiple visits, we randomly selected one to serve as the index
encounter. Study-eligible patients were aged 20–89 years, had
at least 1 year of continuous health plan enrolment and pre-
scription drug coverage prior to the index outpatient visit (i.e.
index date), and had no evidence of CDI (e.g. diagnosis code,
positive test result, or vancomycin dispensing) in the 180 days
before and including the index date. Patients were allowed to
have up to a 90-day gap in enrolment and still be considered to
be ‘continuously’ enrolled. The same inclusion and exclusion
criteria were used for the development and validation cohorts.
During the study time period, each of these health plans had
~450 000 members. Electronic databases provided information
about enrolment, pharmacy dispensing, demographics, and
clinical measures, including diagnoses, laboratory results, and
healthcare utilization. The study was approved by Institutional
Review Boards at both health plans.
Outcome measurement
We followed patients from their index date until the ﬁrst
observed CDI or for 12 months, whichever came ﬁrst. We
analysed time to ﬁrst occurrence of CDI, deﬁned as: (a) an
International Classiﬁcation of Diseases, 9th Revision (ICD-9)
diagnosis code 008.45 for ‘Intestinal infection due to C. difﬁcile’
from an outpatient encounter or hospitalization; or (b) aClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologypositive C. difﬁcile toxin test in the outpatient setting. We also
required positive toxin test results to be associated with (a)
outpatient dispensing of metronidazole or vancomycin in the 7
days before or after the result date, or (b) an encounter for
C. difﬁcile (ICD-9 code 008.45) in the 7 days after the result
date.
The CDI incident date was deﬁned by the ﬁrst indication of
CDI (e.g. diagnosis code; date of vancomycin dispensing prior to
a positive test). We did not follow patients after the ﬁrst
observed CDI. Patients were censored upon death or discon-
tinuation of health plan enrolment. We also did not follow
patients after 30 September 2008; thus, individuals with an in-
dex date after 30 September 2007 had <1 year of follow-up.
Predictors of CDI
We identiﬁed predictors of CDI from a review of the scientiﬁc
literature [2–7]. We sought to develop a pragmatic risk score;
thus, we considered the ease and reliability with which char-
acteristics could be accessed from the electronic medical re-
cord (EMR) and the population prevalence of each
characteristic. To avoid over-ﬁtting to the development data,
we limited the number of potential characteristics and their
degrees of freedom [18].
Patient characteristics were obtained from coded informa-
tion in the EMR. For time-varying characteristics—such as
healthcare utilization, medication use, renal dialysis, and
chemotherapeutic therapies—we collected data for the 60-day
period before the index visit. The presence of comorbid con-
ditions was assessed in the 1 year before the index date.
Diagnosis codes and speciﬁc medications used to identify risk
score characteristics are available upon request.
Development of the CDI risk score among the KPNW
population
We used Cox regression to evaluate baseline characteristics
that might predict CDI in the 1 year following an outpatient
visit. Statistical signiﬁcance did not guide the development of the
model. Instead, we included all predictors identiﬁed a priori. We
modelled categorical variables by using indicator variables.
Continuous variables were modelled by use of a restricted
cubic spline, which is one approach for describing a non-linear
relationship between a predictor and an outcome [19]. The
number and location of the knots for each restricted cubic
spline were based on sample size, number of events, and
available degrees of freedom relative to the expected explan-
atory power of each variable [20]. We included all a priori
baseline characteristics, although we observed too few CDI
events to evaluate interactions between characteristics.
We translated the Cox regression coefﬁcients into a points-
based risk score in which a higher number of points indicates aand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 256–262
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the Cox model was mapped to the corresponding 1-year CDI
risk. The components of the linear predictor were then
rescaled to an arbitrary axis in which a score of zero points was
assigned to the lowest-risk category for each variable, with
increasing points representing proportionate increases in the
linear predictor. These risk score points approximate the
hazard ratio for CDI. The points-based risk score offers
decision-makers a practical tool for approximating the risk of
CDI without the need to calculate the risk by using the full Cox
regression equation and its coefﬁcients.
Evaluation of risk score performance
We assessed predictive performance of the Cox model in the
development cohort by examining discrimination, a measure of
how well the model distinguishes who will and will not develop
CDI, and calibration, a measure of how closely the predictedTABLE 1. Baseline characteristics for patients without Clostridium
(KPNW) development and Kaiser Permanente Colorado (KPCO
cohort who experienced CDI during the 1 year after an outpatient
Patient characteristics
KPNW
Patients without
CDI (n [ 356 312)
Age (years), mean (SD) 48.2 (16.5)
Age (years), n (%)
20–29 54 859 (15.4)
30–39 63 652 (17.9)
40–49 70 472 (19.8)
50–59 77 359 (21.7)
60–69 50 303 (14.1)
70–79 25 118 (7.1)
80–89 14 549 (4.1)
Female, n (%) 195 947 (55.0)
Days of hospitalization in the previous 60 days
0 346 150 (97.2)
1–6 8431 (2.4)
7 1731 (0.5)
Stay in a communal-living healthcare facility
in the previous 60 days, n (%)
710 (0.2)
Chronic kidney disease, n (%)
No diagnosis of chronic kidney disease and
no history of dialysis
350 565 (98.4)
Chronic kidney disease diagnosis and no
history of dialysis
4653 (1.3)
History of dialysis 1094 (0.3)
Inﬂammatory bowel disease, n (%) 1976 (0.6)
Immunosuppression in the previous 60 days, n (%) 13 415 (3.8)
Chronic pulmonary disease, n (%) 40 568 (11.4)
Rheumatological disease, n (%) 3422 (0.96)
Diabetes, n (%) 31 801 (8.9)
Cardiovascular disease, n (%) 20 546 (5.8)
Liver disease, n (%) 969 (0.3)
Malignancy and metastatic solid tumour, n (%) 11 814 (3.3)
Chemotherapeutic procedures or therapies in the
previous 60 days, n (%)
15 816 (4.4)
Use of β-lactam/β-lactamase inhibitors in the
previous 60 days, n (%)
10 425 (2.9)
Use of cephalosporins in the previous 60 days, n (%) 7608 (2.1)
Use of clindamycin in the previous 60 days, n (%) 2528 (0.7)
Use of ﬂuoroquinolones in the previous 60 days, n (%) 6049 (1.7)
Use of macrolides in the previous 60 days, n (%) 5239 (1.5)
Use of sulphonamides in the previous 60 days, n (%) 5788 (1.6)
Use of tetracyclines in the previous 60 days, n (%) 5696 (1.6)
Use of gastric acid suppressants in the previous
60 days, n (%)
32 454 (9.1)
SD, standard deviation.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectrisk agrees with what was actually observed. We measured
discrimination by the use of Harrell’s C-statistic [21,22], the D-
statistic, and the R2-statistic. Harrell’s C-statistic measures the
proportion of all patient pairs in which predictions and out-
comes are concordant. The D-statistic measures separation of
survival curves. The R2-statistic measures variation in CDI risk
explained by the model. To show discrimination and calibration,
we also plotted failure curves for observed and predicted CDI
risk among KPNW patients according to deciles of predicted
risk, as determined by the model [23].
External validation of the CDI risk score among the
KPCO population
Because decision-makers in other settings are more likely to
use a points-based risk score than a Cox regression equation,
we validated CDI predictions in the KPCO population by using
our points-based risk score. Using patient-level data from thedifﬁcile infection (CDI) in the Kaiser Permanente Northwest
) validation cohorts and the subgroup of patients in each
visit
KPCO
Patients with
CDI (n [ 608)
Patients without
CDI (n [ 295 930)
Patients with
CDI (n [ 620)
64.9 (16.9) 49.6 (17.2) 66.9 (16.5)
22 (3.6) 42 718 (14.4) 17 (2.7)
36 (5.9) 51 225 (17.3) 35 (5.7)
52 (8.6) 56 996 (19.3) 48 (7.7)
94 (15.5) 59 652 (20.1) 85 (13.7)
128 (21.1) 41 042 (13.9) 103 (16.6)
126 (20.7) 30 315 (10.2) 162 (26.1)
150 (24.7) 13 982 (4.7) 170 (27.4)
353 (58.1) 167 094 (56.5) 377 (60.8)
493 (81.1) 285 769 (96.6) 505 (81.5)
59 (9.7) 8786 (3.0) 69 (11.1)
56 (9.2) 1375 (0.5) 46 (7.4)
33 (5.4) 884 (0.3) 35 (5.7)
509 (83.7) 283 538 (95.8) 472 (76.1)
73 (12.0) 11 484(3.9) 111 (17.9)
26 (4.3) 908 (0.3) 37 (6.0)
16 (2.6) 1221 (0.4) 13 (2.1)
107 (17.6) 11 602 (3.9) 128 (20.7)
163 (26.8) 33 615 (11.4) 181 (29.2)
26 (4.3) 3529 (1.2) 33 (5.3)
165 (27.1) 23 566 (8.0) 139 (22.4)
195 (32.1) 23 164 (7.9) 202 (32.6)
14 (2.3) 762 (0.3) 14 (2.3)
94 (15.5) 12 210 (4.1) 119 (19.2)
86 (14.1) 16 367 (5.5) 111 (17.9)
53 (8.7) 10 181 (3.4) 45 (7.3)
74 (12.2) 4361 (1.5) 30 (4.8)
36 (5.9) 2084 (0.7) 17 (2.7)
65 (10.7) 5831 (2.0) 84 (13.6)
30 (4.9) 4286 (1.5) 20 (3.2)
27 (4.4) 3138 (1.1) 23 (3.7)
15 (2.5) 5070 (1.7) 17 (2.7)
161 (26.5) 27 491 (9.3) 136 (21.9)
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TABLE 2. Adjusted hazard ratios and number of risk score points for patient characteristics included in the Cox regression model
to predict Clostridium difﬁcile infection during the 1 year after an outpatient visit among Kaiser Permanente Northwest members
Patient characteristics Hazard ratio (95% CI) Risk points
Age (years)a
20–24 — 2
25–29 — 3
30–34 — 5
35–39 — 8
40–44 — 12
45—49 — 18
50–54 — 28
55–59 — 38
60–64 — 49
65–69 — 59
70–74 — 69
75–79 — 79
80–84 — 90
85–89 — 100
Sex
Male Reference 0
Female 1.16 (0.99–1.37) 6
Days of hospitalization in the previous 60 days, n (%)
0 Reference 0
1–6 1.21 (0.89–1.64) 8
7 2.42 (1.67, 3.51) 37
Stay in a communal-living healthcare facility, n (%)
No stay Reference 0
History of a stay 1.78 (1.18–2.68) 24
Chronic kidney disease, n (%)
No diagnosis of chronic kidney disease and no history of dialysis Reference 0
Chronic kidney disease diagnosis and no history of dialysis 2.14 (1.62–2.84) 32
History of dialysis 1.83 (1.16–2.91) 25
IBD, n (%)
No IBD Reference 0
IBD 2.83 (1.71–4.67) 43
Immunosuppression, n (%)
No immunosuppression Reference 0
Immunosuppression 1.72 (1.34–2.20) 22
Chronic pulmonary disease, n (%)
No chronic pulmonary disease Reference 0
Chronic pulmonary disease 1.15 (0.95–1.4) 6
Rheumatological disease, n (%)
No rheumatological disease Reference 0
Rheumatological disease 1.13 (0.75–1.72) 5
Diabetes, n (%)
No diabetes Reference 0
Diabetes 1.36 (1.11–1.66) 13
Cardiovascular disease, n (%)
No cardiovascular disease Reference 0
Cardiovascular disease 1.57 (1.26–1.94) 19
Liver disease, n (%)
No liver disease Reference 0
Liver disease 3.13 (1.83–5.36) 47
Malignancy and metastatic solid tumour, n (%)
No malignancy or metastatic solid tumour Reference 0
Malignancy or metastatic tumour 1.72 (1.35–2.18) 22
Chemotherapeutic procedures or therapies, n (%)
No chemotherapy Reference 0
Chemotherapy 1.34 (1.05–1.72) 12
Use of β-lactam/β-lactamase inhibitors, n (%)
No use Reference 0
Any use 1.93 (1.45–2.58) 27
Use of cephalosporins, n (%)
No use Reference 0
Any use 2.51 (1.94–3.3) 38
Use of clindamycin, n (%)
No use Reference 0
Any use 4.1 (2.89–5.82) 58
Use of ﬂuoroquinolones, n (%)
No use Reference 0
Any use 1.84 (1.39–2.43) 25
Use of macrolides, n (%)
No use Reference 0
Any use 1.66 (1.13–2.43) 21
Use of sulphonamides, n (%)
No use Reference 0
Any use 1.17 (0.79–1.74) 6
Use of tetracyclines, n (%)
No use Reference 3
Any use 0.94 (0.56–1.58) 0
Use of gastric acid suppressants, n (%)
No use Reference 0
Any use 1.34 (1.1–1.63) 12
IBD, inﬂammatory bowel disease.
aAge was modelled by the use of restricted cubic splines; the method does not give a summary hazard ratio and CI per unit increase.
CMI Kuntz et al. Predicting C. difﬁcile after an outpatient visit 259
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 256–262
260 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIKPCO cohort, we ‘scored’ each patient according to their
baseline characteristics. After calculating each patient’s risk
score points, we were able to approximate their predicted 1-
year risk for CDI. (Appendix 1 includes a summary table of
the relationship between risk score points and the predicted 1-
year risk; the complete version of the table is available upon
request.)
Using KPCO data that included each patient’s total risk score
points and whether or not the patient actually developed CDI,
we were able to ﬁt a logistic regression model and calculate the
area under the receiver operating characteristic (ROC) curve,
which assesses discrimination—similar to the C-statistic. We
repeated those steps for the KPNW cohort to calculate its area
under the ROC curve, so that we could compare directly the
performance for the points-based risk score (instead of the
Cox regression equation and its exact coefﬁcients).
We then divided the KPCO cohort into deciles of predicted
risk. For each decile of predicted risk, we used patient-level
data to calculate the Kaplan–Meier observed 1-year risk for
CDI to assess calibration. We plotted those observed and
predicted risks by decile for the KPCO cohort. Statisticians
refer to this approach as a level 2 external validation of the Cox
model, because it applies the risk score from a development
population to a new population to assess discrimination and
calibration [24].ResultsFIG 1. Failure curves showing the observed risk (solid lines) and the
predicted risk (dotted lines) of Clostridium difﬁcile infection during the
ﬁrst year after an outpatient visit among Kaiser Permanente Northwest
patients according to deciles of predicted risk, as determined by the risk
score.Development of the risk score among the KPNW
population
Among 356 920 KPNW patients with an index outpatient visit,
we observed 608 CDIs, giving a 1-year incidence of 2.2 CDIs
per 1000 patients (95% CI 2.0–2.4). Patients who developed
CDI were older and more likely to have a history of hospital-
ization or a stay in a communal-living healthcare facility
(Table 1). Patients who developed CDI were also more likely to
have recently received antibiotics and gastric acid suppressants
or to have a history of immunosuppression or chemotherapy.
All comorbid conditions occurred more frequently among pa-
tients who developed CDI.
The patient characteristics that contributed >30 points to
the risk score, indicating an approximate doubling of risk, were:
age of 55 years (38–100 points, depending on age category);
hospitalization of 7 days (37 points); liver disease (47 points);
inﬂammatory bowel disease (43 points); and cephalosporin use
(38 points) or clindamycin use (58 points) (Table 2). The 22
characteristics in the score accounted for 27 degrees of
freedom. The slope-shrinkage statistic, which assesses the
extent to which the model may be over-ﬁtted to theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectdevelopment data, was 0.99 (on a scale from 0 to 1, where 1
indicates no over-ﬁtting).
Summary statistics from the internal validation of the pre-
diction model indicated effective performance in the KPNW
cohort. Patients in the highest-risk decile were nearly 60 times
more likely to suffer a CDI (1-year incidence of 9.8 CDIs/1000
patients) than patients in the lowest-risk decile (0.2 CDIs/1000
patients) (Fig. 1). The bootstrap-corrected C-statistic (0.83) and
the D-statistic (2.35) indicate effective discrimination or sepa-
ration of the high-risk and low-risk patients. The R2-statistic
(56.82) indicates that the prediction model explained 56.82% of
the variation in CDI risk. The predicted risk was closely aligned
with observed events for the highest-risk patients. Agreement
(calibration) was adequate for the remaining deciles (Fig. 1). The
simpler points-based risk scoring system retained its effective
discrimination, although it was less effective than the prediction
model based on the Cox regression equation with exact co-
efﬁcients (area under the ROC curve of 0.786).
External validation of risk score among the KPCO
population
We validated the score among 296 550 similarly-deﬁned KPCO
patients; 620 of these patients experienced CDI, yielding a 1-
year incidence of 2.3 CDIs per 1000 patients (95% CI
2.1–2.5). Table 1 shows the baseline characteristics for KPCO
patients. The simpler, points-based risk score (developed in the
KPNW cohort) performed comparably in the KPCO cohort in
terms of discrimination, as shown by the area under the ROCious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 256–262
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agreement, of the points-based risk score for each decile of
predicted risk.DiscussionWe developed and validated a risk score that successfully
discriminated between patients at the highest and lowest risk
for CDI. Our predictions agreed closely with the observed risk
for CDI. The risk score provides important information about
CDI risk for patients who are most likely to beneﬁt from
clinician recognition of this risk, and for speciﬁc clinical
decision-making, clinical monitoring, and/or education. For
example, in the KPNW population, using our risk score could
help clinicians to focus on the 10% of patients who will expe-
rience 57% of the CDIs.
Our risk score is the ﬁrst to be developed and externally
validated to predict incident infection in an unselected, outpa-
tient routine care setting. This reliable and accurate tool will
enable clinicians to use combinations of predictors to estimate
the probability that CDI will occur, and to identify patients in
whom recognition of elevated risk can prompt risk manage-
ment efforts (e.g. more judicious antimicrobial use). In the
future, this score might be used to select high-risk patients for
clinical trials, or in turn, to determine patients for whom pri-
mary prevention (i.e. vaccination) would be warranted.
For example, on the basis of this model, practitioners might
choose a threshold for targeting patients for increased risk0
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FIG 2. Observed and predicted risk of Clostridium difﬁcile infection
during the ﬁrst year after an outpatient visit among Kaiser Permanente
Colorado patients, according to deciles of predicted risk as determined
by application of the points-based risk score. The ﬁgure demonstrates
successful calibration for each decile of predicted risk. For instance, in
the top decile of predicted risk, the predicted risk was slightly lower
than the observed risk.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologymanagement. To illustrate: if a physician chose the 90th
percentile of the risk score (i.e. the top decile) as a threshold,
he or she would focus attention on patients who experienced
57.2% of CDIs (95% CI 53.2–61.2%). The speciﬁcity for that
threshold is 90.3% (95% CI 90.2–90.4%). One per cent of pa-
tients in the top decile developed CDI (positive predictive value
of 1%; 95% CI 0.9–1.11%). The negative predictive value was
99.9% (95% CI 99.9–99.9%). In order to score in this top
decile, a patient would require at least 90 risk points. As an
example, a 65-year-old patient with diabetes and recent ﬂuo-
roquinolone use would score 97 points (age 65 years (59
points) + history of diabetes (13 points) + ﬂuoroquinolone use
(25 points) = 97 points).
We developed our risk score to be pragmatic, meaning that
this score can be easily calculated from readily available clinical
and non-clinical information to inform decision-making at the
point of care. In usual care, clinicians assess risk on the basis of
known risk factors, although the complexity of such calculations
can often be overwhelming, requiring physicians to consider
individual factors without the support of a statistical algorithm
to account for relationships between individual characteristics
[25,26]. In contrast, our risk score is designed to work with
data that are routinely collected and available, allowing for a
patient’s CDI risk to be automatically calculated and made
directly available to clinicians via an EMR.
Our study has limitations. First, we did not include patients
with a recent history of CDI, so the risk score is not tailored to
estimate the risk of CDI recurrence. Second, we did not
measure antimicrobial or other medication use during hospi-
talization. Next, because information about the date of micro-
biological testing and treatments dispensed were unavailable for
hospitalized patients, we limited our identiﬁcation of CDI in the
inpatient setting to the use of diagnosis codes. Finally, it should
be noted that the accuracy of the risk score’s predictions and
the low incidence of CDI mean that the positive predictive
value is low; that is, most patients designated as ‘high risk’ will
not go on to develop CDI.
Our risk score successfully discriminates between patients at
the highest and lowest risk for CDI among patients seeking
outpatient care. Clinicians who wish to use this risk score may
want to validate its predictions in their populations and
healthcare settings. Future efforts should focus on determining
the impact of the risk score on patient management and out-
comes, as compared with usual care [25].Transparency declarationFinancial support for this study was provided by a contract with
Sanoﬁ Pasteur. The funding agreement ensured the authors’and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 256–262
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corresponding ranges of predicted
probabilities for Clostridium difﬁcile infection
in the 1 year following an outpatient visit
Risk score points Predicted risk (%)Clinical Microbiology and Infection © 2014 European Society of0–128 <1.00
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217–221 8.00–8.99
222–225 9.00–9.99
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